CA2427583C - Inhalable formulation of a solution containing a tiotropium salt - Google Patents

Inhalable formulation of a solution containing a tiotropium salt Download PDF

Info

Publication number
CA2427583C
CA2427583C CA002427583A CA2427583A CA2427583C CA 2427583 C CA2427583 C CA 2427583C CA 002427583 A CA002427583 A CA 002427583A CA 2427583 A CA2427583 A CA 2427583A CA 2427583 C CA2427583 C CA 2427583C
Authority
CA
Canada
Prior art keywords
pharmaceutical preparation
preparation according
tiotropium
acid
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002427583A
Other languages
English (en)
French (fr)
Other versions
CA2427583A1 (en
Inventor
Karin Drechsel
Barbara Niklaus-Humke
Christel Schmelzer
Petra Barth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7661727&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2427583(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Publication of CA2427583A1 publication Critical patent/CA2427583A1/en
Application granted granted Critical
Publication of CA2427583C publication Critical patent/CA2427583C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
CA002427583A 2000-10-31 2001-10-24 Inhalable formulation of a solution containing a tiotropium salt Expired - Fee Related CA2427583C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10054042 2000-10-31
DE10054042.2 2000-10-31
PCT/EP2001/012296 WO2002036591A2 (de) 2000-10-31 2001-10-24 Inhalative lösungsformulierung mit einem tiotropiumsalz

Publications (2)

Publication Number Publication Date
CA2427583A1 CA2427583A1 (en) 2002-05-10
CA2427583C true CA2427583C (en) 2008-02-12

Family

ID=7661727

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002427583A Expired - Fee Related CA2427583C (en) 2000-10-31 2001-10-24 Inhalable formulation of a solution containing a tiotropium salt

Country Status (33)

Country Link
EP (1) EP1335729A2 (es)
JP (1) JP4559703B2 (es)
KR (1) KR100983208B1 (es)
CN (1) CN1237970C (es)
AR (1) AR038765A1 (es)
AU (2) AU2174102A (es)
BG (1) BG66425B1 (es)
BR (1) BR0115016A (es)
CA (1) CA2427583C (es)
CZ (1) CZ305033B6 (es)
DE (1) DE10152369A1 (es)
EA (1) EA009068B1 (es)
EC (1) ECSP034570A (es)
EE (1) EE05343B1 (es)
HK (1) HK1060569A1 (es)
HR (1) HRP20030337A2 (es)
HU (1) HUP0301377A3 (es)
IL (2) IL155676A0 (es)
ME (1) ME00242B (es)
MX (1) MXPA03003750A (es)
MY (1) MY132777A (es)
NO (1) NO332524B1 (es)
NZ (1) NZ526024A (es)
PE (1) PE20020518A1 (es)
PL (1) PL361001A1 (es)
SA (1) SA01220503B1 (es)
SK (1) SK288031B6 (es)
TW (1) TWI296934B (es)
UA (1) UA76435C2 (es)
UY (1) UY26991A1 (es)
WO (1) WO2002036591A2 (es)
YU (1) YU33103A (es)
ZA (1) ZA200303045B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60114865T2 (de) 2000-04-28 2006-07-27 Kosan Biosciences, Inc., Hayward Heterologe herstellung von polyketiden
US20030235538A1 (en) 2002-04-09 2003-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for the administration of an anticholinergic by inhalation
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
AU2004279438A1 (en) * 2003-10-09 2005-04-21 Inverseon, Inc. Methods for treating diseases and conditions with inverse agonists
SE0303269L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Medicinsk produkt
CA2595791C (en) * 2005-03-16 2013-10-08 Meda Pharma Gmbh & Co. Kg The combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases
US20070274925A1 (en) * 2006-05-26 2007-11-29 Dey, L.P. Nebulizable compositions of quaternary ammonium muscarinic receptor antagonists
CN100446770C (zh) * 2007-01-10 2008-12-31 上海现代药物制剂工程研究中心有限公司 丙酸培氯米松水雾剂
TR200907237A2 (tr) * 2009-09-23 2011-04-21 Bi̇lgi̇ç Mahmut Tiotropyum kuru toz kombinasyonu
CN116173025A (zh) * 2018-07-26 2023-05-30 四川海思科制药有限公司 一种含格隆铵盐及茚达特罗盐的气雾剂药物组合物及其制备方法与应用
CN111971034A (zh) * 2018-07-26 2020-11-20 四川海思科制药有限公司 一种含格隆铵盐的气雾剂药物组合物及其制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0504112A3 (en) * 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
DE4203306A1 (de) * 1992-02-06 1993-08-12 Ig Spruehtechnik Gmbh Asthma oder pulmonal-aerosolzubereitungen mit lecithin
DK0835098T3 (da) * 1995-06-27 2002-10-07 Boehringer Ingelheim Pharma Stabilt lægemiddelpræparat til frembringlese af drivgasfrie aerosoler
US5824669A (en) * 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
BR9709650A (pt) * 1996-06-04 1999-08-10 Procter & Gamble Aerosol nasal contendo um esteróide intransal e um anti-histamínico
DE19653969A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
JPH10298107A (ja) * 1997-04-25 1998-11-10 Taisho Pharmaceut Co Ltd 医薬組成物
DK1102579T3 (da) * 1998-08-04 2003-07-14 Jago Res Ag Medicinske aerosolformuleringer
DE19847968A1 (de) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Verschlußkappe und Behälter als Zweikammer-Kartusche für Vernebler zur Erzeugung von Aerosolen

Also Published As

Publication number Publication date
CZ20031487A3 (cs) 2003-09-17
YU33103A (sh) 2006-05-25
MEP40708A (en) 2011-02-10
AU2174102A (en) 2002-05-15
BR0115016A (pt) 2005-05-03
SK5262003A3 (en) 2003-10-07
AU2002221741B2 (en) 2007-04-05
EE200300202A (et) 2003-10-15
CN1473044A (zh) 2004-02-04
KR100983208B1 (ko) 2010-09-20
HUP0301377A2 (hu) 2003-10-28
DE10152369A1 (de) 2002-05-08
NO332524B1 (no) 2012-10-08
PL361001A1 (en) 2004-09-20
CA2427583A1 (en) 2002-05-10
ME00242B (me) 2011-05-10
MXPA03003750A (es) 2004-10-15
EP1335729A2 (de) 2003-08-20
AR038765A1 (es) 2005-01-26
SK288031B6 (sk) 2012-12-03
EA009068B1 (ru) 2007-10-26
NO20031914L (no) 2003-06-23
NO20031914D0 (no) 2003-04-29
PE20020518A1 (es) 2002-07-12
MY132777A (en) 2007-10-31
NZ526024A (en) 2005-10-28
WO2002036591A3 (de) 2002-07-25
SA01220503B1 (ar) 2007-03-10
HRP20030337A2 (en) 2005-04-30
BG107726A (bg) 2004-11-30
HK1060569A1 (en) 2004-08-13
CZ305033B6 (cs) 2015-04-08
IL155676A (en) 2012-05-31
UY26991A1 (es) 2002-06-20
UA76435C2 (en) 2006-08-15
ECSP034570A (es) 2003-06-25
IL155676A0 (en) 2003-11-23
WO2002036591A2 (de) 2002-05-10
TWI296934B (en) 2008-05-21
JP2004523482A (ja) 2004-08-05
JP4559703B2 (ja) 2010-10-13
KR20040010552A (ko) 2004-01-31
EE05343B1 (et) 2010-10-15
BG66425B1 (bg) 2014-04-30
ZA200303045B (en) 2004-04-22
EA200300483A1 (ru) 2003-12-25
HUP0301377A3 (en) 2005-12-28
CN1237970C (zh) 2006-01-25

Similar Documents

Publication Publication Date Title
US6890517B2 (en) Inhalable formulation of a solution containing a tiotropium salt
US20020111363A1 (en) Inhalable formulation of a solution containing a tiotropium salt
US20120189556A1 (en) Pharmaceutical compositions based on anticholinergics and corticosteroids
JP2005068163A (ja) チオトロピウム塩及びサルメテロール塩に基づく新規医薬組成物
US20110038806A1 (en) Medicaments for inhalation comprising an anticholinergic and a steroid
CA2427583C (en) Inhalable formulation of a solution containing a tiotropium salt
CA2473815C (en) Aerosol formulation for inhalation containing a tiotropium salt
CA2426074C (en) Inhalable formulation of a solution containing a tiotropium salt
CA2534128C (en) Combination of an anticholinergic and a steroid and its use to treat respiratory disorders by inhalation
JP2004512379A (ja) 新規医薬組成物
CA2738616A1 (en) Aerosol formulation for the inhalation of beta agonists
EP2358350A1 (en) Aerosol formulation for the inhalation of beta agonists

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20201026